Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMPAS metabolomic profiling study in patients receiving gemcitabine
NL-OMON57860Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gemcitabine in Nonhematologic neoplasms, sponsored by Erasmus MC. Primary endpoint: Changes in metabolomic profile at end of gemcitabine infusion. Started Dec 2025; status: completed.
02
Drugs
gemcitabine
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON57860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57860.